Nuclear-Targeting Lipid Pt IV Prodrug Amphiphile Cooperates with siRNA for Enhanced Cancer Immunochemotherapy by Amplifying Pt-DNA Adducts and Reducing Phosphatidylserine Exposure
Journal of the American Chemical Society · 2024
DOI: 10.1021/jacs.3c12706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2024. Verfasst von Dengshuai Wei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy and Department of Epidemiology and Health Statistics, School of Public Health, Qingdao University, Qi…. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Natural Science Foundation of Qingdao Municipality, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Patients treated with Pt-based anticancer drugs (PtII) often experience severe side effects and are susceptible to cancer recurrence due to the limited bioavailability of PtII and tumor-induced immunosuppression. The exposure of phosphatidylserine on the cell's outer surface induced by PtII results in profound immunosuppression through the binding of phosphatidylserine to its receptors on immune cells. Here, we report a novel approach for enhanced cancer chemoimmunotherapy, where a novel nuclear-targeting lipid PtIV prodrug amphiphile was used to deliver a small interfering RNA (siXkr8) to simultaneously amplify Pt-DNA adducts and reduce the level of exposure of phosphatidylserine. This drug delivery vehicle is engineered by integrating the PtIV prodrug with self-assembly performance and siXkr8 into a lipid nanoparticle, which shows tumor accumulation, cancer cell nucleus targeting, and activatable in a reduced microenvironment. It is demonstrated that nuclear-targeting lipid PtIV prodrug increases the DNA cross-linking, resulting in increased Pt-DNA adduct formation. The synergistic effects of the PtIV prodrug and siXkr8 contribute to the improvement of the tumor immune microenvironment. Consequently, the increased Pt-DNA adducts and immunogenicity effectively inhibit primary tumor growth and prevent tumor recurrence. These results underscore the potential of utilizing the nuclear-targeting lipid PtIV prodrug amphiphile to enhance Pt-DNA adduct formation and employing siXkr8 to alleviate immunosuppression during chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy and Department of Epidemiology and Health Statistics, School of Public Health, Qingdao University, Qingdao 266021, China.
- School of Dentistry, The University of Queensland, Brisbane 4006, Australia.
- Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics and Chemistry, Institute of Chemistry Chinese Academy of Sciences, Beijing 100190, China.
ORCID-Profile: Chaolong Liu, Chun Xu, Yong Sun, Haihua Xiao
Förderung
- Natural Science Foundation of Qingdao Municipality
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Wei, D., Fan, J., Yan, J., Liu, C., Cao, J., Xu, C., Sun, Y., & Xiao, H. (2024). Nuclear-Targeting Lipid Pt IV Prodrug Amphiphile Cooperates with siRNA for Enhanced Cancer Immunochemotherapy by Amplifying Pt-DNA Adducts and Reducing Phosphatidylserine Exposure. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.3c12706
Vancouver
Wei D, Fan J, Yan J, Liu C, Cao J, Xu C, et al. Nuclear-Targeting Lipid Pt IV Prodrug Amphiphile Cooperates with siRNA for Enhanced Cancer Immunochemotherapy by Amplifying Pt-DNA Adducts and Reducing Phosphatidylserine Exposure. Journal of the American Chemical Society. 2024. doi:10.1021/jacs.3c12706
BibTeX
@article{Wei2024,
author = {Wei, Dengshuai and Fan, Junning and Yan, Jianqin and Liu, Chaolong and Cao, Jie and Xu, Chun and Sun, Yong and Xiao, Haihua},
title = {Nuclear-Targeting Lipid Pt IV Prodrug Amphiphile Cooperates with siRNA for Enhanced Cancer Immunochemotherapy by Amplifying Pt-DNA Adducts and Reducing Phosphatidylserine Exposure},
journal = {Journal of the American Chemical Society},
year = {2024},
doi = {10.1021/jacs.3c12706}
}
EUVIMED